Clinical trial
Phase II Evaluation of Pyrazoloacridine (NSC #366140) in Patients With Metastatic Breast Cancer
NCT00003041 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Evaluation of Pyrazoloacridine (NSC #366140) in Patients With Metastatic Breast Cancer
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 1997
- Completion date
- January 31, 2002
- Enrollment
- Not reported
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer